Investing & trading with exchange-traded funds (ETFs) and closed-end funds (CEFs). Strategies & analysis but no buy or sell recommendations.

Visit SeekingAlpha ETFs

Onyx Pharmaceuticals: Could Acquiring Proteolix Be the Deal of the Year?

Posted on October 22, 2009

Onyx s (ONXX) stock decline in the past few months puzzled its shareholders. Nothing that has come in the news in the past year has been bad. On the contrary, a string of promising results was incessantly coming from the clinical trials of the firm s cancer drug Nexavar on a variety of cancers. Now there are sufficient data to get an approval for other malignancies, including breast cancers. The drug was first approved for kidney cancer and then for liver cancer and, for a long while, there was no evidence that it would be approved for other cancers. Shareholders, though, did not lose hop...

Original article link


data